The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices that go into effect in 2027.
Continue readingCategory Archives: Uncategorized
Why 2025 is set to be a crucial year for Amazon’s Zoox robotaxi unit
This year is expected to be a crucial one for Amazon’s Zoox, as the company plans to grow its operations and commercialize a robotaxi business.
Continue readingSpaceX catches Starship booster again as rocket continues on in space
SpaceX launched the seventh test flight of its Starship rocket on Thursday.
Continue readingWall Street banks had a great quarter, and the boom times are just starting
JPMorgan Chase, Goldman Sachs and Morgan Stanley easily topped estimates for the fourth quarter.
Continue readingInvestors pitch new international basketball league that would offer players equity
The investors are looking to raise $5 billion to start a basketball league that could offer players equity to potentially lure them away from the […]
Continue readingLIV Golf announces multiyear media rights deal with Fox Sports
LIV Golf announced a media rights agreement with Fox Sports to broadcast the pro golf tour to U.S. viewers just one day after naming a […]
Continue readingJPMorgan Chase is boosting buybacks even after CEO Jamie Dimon called the stock expensive
Fresh off a record year for profit and revenue, JPMorgan is facing questions over what CFO Jeremy Barnum admitted was excess capital.
Continue readingFTC sues Deere, alleging equipment repair ‘monopoly’ raises costs for farmers
The Federal Trade Commission has filed a lawsuit against agricultural equipment giant Deere & Company, alleging it holds a monopoly on repair services.
Continue readingBlue Origin’s first New Glenn rocket reaches orbit, misses booster landing
Blue Origin launched its towering New Glenn rocket for the first time early Monday, in a crucial milestone for Jeff Bezos’ space company.
Continue readingMedicare’s new $2,000 cap on out-of-pocket drug costs could save patients thousands, AARP says
The AARP report suggests the spending cap could be huge for Medicare enrollees who take costly drugs for cancer, rheumatoid arthritis, and other conditions.
Continue reading